retatrutide description Retatrutide: Fat Loss, Liver Health & Muscle Care RETATRUTIDE (RETA)

It remains an experimental therapy, and patients should not attempt to obtain it outside of regulated clinical trial settings

Relatively common side effects Internal bleeding or itching at the injection site, diarrhea, constipation, headache Severe side effects hypoglycemia, pancreatitis, bowel obstruction, palpitations *Although GLP-1 alone rarely causes hypoglycemia, it has been reported that combined use with insulin or oral hypoglycemic agents can cause severe hypoglycemia

The answer is no, and attempting to do so typically costs more in the long run

GLP-1-based therapies led to favorable changes in body composition, with significant reductions in VAT and FBM, particularly during the first six months

This exceeds a standard 1mL syringe

In April 2025 the A4PC published direct guidance telling members not to compound retatrutide